查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853632

心血管吻合器市场按产品类型、机制、手术类型和最终用户划分 - 全球预测 2025-2032 年

Cardiovascular Anastomosis Devices Market by Product Type, Mechanism, Procedure Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，心血管吻合装置市场规模将成长 45.5 亿美元，复合年增长率为 11.00%。

关键市场统计数据
基准年 2024 19.7亿美元
预计年份：2025年 21.9亿美元
预测年份 2032 45.5亿美元
复合年增长率 (%) 11.00%

对目前心血管吻合术的设备生态系统、临床考量和营运重点进行清晰权威的阐述

心血管吻合装置融合了外科技术、材料科学和系统级医疗服务。本文概述了目前用于建立和固定血管及心臟连接的各种手术工具，重点阐述了装置外形规格、作用机制和临床工作流程如何相互作用并影响手术结果。该领域正从手动缝合发展到机械化、能量辅助和混合式解决方案，旨在提高手术的可重复性、缩短手术时间并减少併发症。

本文介绍的各类器械中，临床医生和医疗机构在评估其性能时，不仅关注易用性，还日益重视耐用性、止血效果以及与微创和机器人手术的兼容性。新型聚合物、金属和能量输送系统的集成，在拓展外科医生选择的同时，也增加了采购、培训和监管流程的复杂性。随着相关人员接受新的方法，器械有效性、临床操作舒适度和手术总成本之间的平衡将成为商业性讨论的核心。

本导言为下一部分奠定了基调，其中包括对正在重塑临床实践的重大变革的分析、主导情景的关税影响分析、阐明产品和临床细分市场的细分洞察，以及旨在为实际策略提供资讯的区域和竞争情报。其目标是为决策者提供清晰的主题要点，以支持其製定短期战术性选择和中期战略规划。

微创趋势、材料突破、器材互通性和不断演变的采购模式如何重新定义外科吻合术

多项变革性变化正在再形成心血管吻合器材的设计、应用和商业化方式，其影响涵盖临床、生产和健保报销等多个领域。首先，微创和机器人辅助手术的稳定发展推动了对能够在有限空间内实现稳定、可重复吻合的器械的需求。这一趋势加速了外形规格以及与机器人平台整合的迭代改进。因此，产品开发如今更加重视模组化介面和相容性标准，从而加快临床应用并减轻训练负担。

其次，从可吸收组件的聚合物配方到止血夹的新型合金和涂层，材料创新正在延长器械的使用寿命并提高其生物相容性，同时使工程师能够缩小器械体积并提高部署可靠性。同时，电热和超音波等能量型技术也不断改进，以减少出血、缩短手术时间，并在与临床适应症适当匹配时提供可控的组织效应。

第三，随着门诊手术中心手术量增加和医院追求基于价值的指标，采购动态也在不断变化。最后，日益增长的监管和临床证据要求促使企业投资于严谨的对照试验和真实世界证据，以证明产品的安全性和有效性，以及下游经济效益和工作流程优化。这些因素共同创造了一种市场环境，在这种环境中，技术差异化、临床检验和分销灵活性将决定医疗器材的市场主导。

对不断变化的美国关税动态将如何推动供应链重组、价格压力以及增强本地製造业韧性的机会进行实际分析

主要市场政策变化导致的关税征收和提高，可能会对心血管吻合器材製造商和经销商的供应链选择、筹资策略和零件经济效益产生重大影响。当进口关税出台或提高时，依赖跨境采购精密金属零件、先进聚合物、电控系统和机器人子系统的公司必须重新评估供应商关係和库存管理，以维持利润率和供货能力。

实际上，关税往往会导致短期成本转嫁给买家，并压缩供应商的利润空间，从而迫使製造商重新设计设备，减少对关税敏感的投入，或认证本地製造商供应关键子组件。製造商可能会寻求建立区域生产基地或签订免收费用製造协议，以减轻定向关税的影响。同时，更高的进口成本可能会加速高关税风险零件的垂直整合，并促使製造商收购或与专业供应商建立合作关係，以确保供应的连续性并降低单位成本波动。

在临床层面，采购团队和医院系统将透过收紧评估标准、增加竞争性竞标以及在适当情况下优先考虑多功能或可重复使用的解决方案来应对关税主导的价格波动。鑑于新的投入成本现实，报销管理人员和价值委员会可能会要求更清晰的成本效益指标。对于推动创新的企业而言，关税既是挑战也是机会。虽然关税可能会加剧短期内的商业性摩擦，但它们也会促进产品简化、敏感供应链的本地化以及渐进式改进的开发，从而减少对进口原材料和成品的依赖。因此，关税情境应纳入策略规划，将其视为持续存在的供应链和定价风险，需要采购、监管事务和产品开发部门协调应对。

整合多维细分，结合产品类型、机制、流程和最终用户参数，揭示精准的临床和商业性目标区域。

了解产品和临床细分市场需要采用多层次的细分方法，以确定最具创新和商业化潜力的目标。产品类型包括夹子、缝合器和缝合线。夹子用于快速血管控制，包括止血夹和血管夹。止血夹本身有金属和聚合物两种材质，需要在耐用性和影像相容性之间进行权衡。缝合器分为圆形和直线型，直线型缝合器又分为非加强型和加强型，以适应不同的组织厚度和防渗漏性能。缝合线分为自动缝合器和手动缝合器，自动缝合器又分为手持缝合器和机器人缝合器。

根据作用机制，止血方法可分为黏合剂、夹持系统、压迫装置、能量型止血方法和缝合器。黏合剂包括生物纤维蛋白胶和合成密封剂，每种密封剂的操作性和止血效果各不相同。压迫装置包括吻合环和扣带，可以是永久性的、可生物吸收的或金属材质的。能量型止血装置利用电热、雷射或超音波来封闭组织并控制出血，同时最大限度地减少热损伤。

冠状动脉绕道术（无论是否体外循环）都面临一系列独特的吻合挑战，而颈动脉、股腘动脉和肾臟介入等周边血管手术则需要针对血管尺寸、可及性和斑块负荷进行优化的器械。瓣膜修復手术还增加了额外的解剖和动态限制，这些限制会影响器械的选择和植入技术。门诊手术中心、医院和专科诊所在设备占地面积、消毒流程和人员训练方面都有不同的要求。了解这些细分层面的相互关联性，有助于企业根据每个不同的临床和营运环境的实际情况，调整产品设计、临床证据产生和商业化路径。

区域临床重点、法规环境和供应链布局将如何影响美洲、欧洲、中东和非洲以及亚太地区的医疗器材采用情况

区域动态影响医疗器材的采纳路径、监管障碍和供应链设计，进而影响策略和执行。在美洲，临床上高度重视微创冠状动脉和周边血管介入治疗，这与成熟的医保报销系统和完善的医院采购流程相辅相成。主要市场的医疗机构优先考虑那些手术时间更短、併发症率更低且能与现有手术平台整合的医疗器材。同时，区域製造商和委託製造在本地化供应和补货方面发挥关键作用，使高容量医疗机构受益。

欧洲、中东和非洲地区（EMEA）是一个异质性区域，各国监管环境和强大的采购机构会在证据确凿时加速产品推广应用，但市场分散也要求制定量身定制的监管和报销策略。一些欧洲市场对真实世界证据和成本效益资料要求很高，采购机构通常要求提供用于永久或半永久使用的医疗设备的长期安全性资讯。

亚太地区的特点是手术量快速增长、医院基础设施投资不断扩大，以及既包括高端三级医疗中心也包括资源有限的医疗机构的双重市场结构。本地原始设备製造商 (OEM) 和区域供应链日益成熟，跨国供应商为了满足监管和成本要求，往往寻求合作伙伴关係和本地化生产。无论在哪个地区，能够使其产品系列与当地手术模式、监管时间表和采购模式相匹配的公司，都将拥有最清晰的持续市场认可路径。

对塑造设备领导地位的竞争定位、伙伴关係关係动态、供应商集中度和创新路径进行了深刻剖析。

心血管吻合器材市场的竞争格局正由成熟的医疗设备製造商、专注于特定领域的中型创新企业以及数量不断增长的科技型新兴企业共同塑造。现有企业正利用其广泛的商业网络、丰富的监管经验和现有的临床关係迅速扩大分销渠道，而规模较小的製造商则致力于开发颠覆性技术——例如先进的能量控制演算法、新型可吸收聚合物和紧凑型机器人缝合模组——以吸引早期采用的外科医生和战略收购方。

医疗器材製造商与机器人平台供应商之间的伙伴关係和共同开发契约日益加强，双方都在寻求互通性和捆绑式临床价值提案。材料科学家、临床研究人员和系统工程师之间的跨学科合作催生了一系列渐进式创新，这些创新改进了操作性、缩小了器械体积并增强了止血效果。同时，监管趋势强调临床证据和上市后监测，提高了新参与企业的进入门槛，使得临床试验设计、註册登记参与和正式的卫生经济学分析成为市场准入计画的必要组成部分。

供应商在专业零件领域的集中化，例如金属夹的精密冲压、客製化聚合物的挤出以及能量输送系统的微电子元件，会造成策略依赖，进而影响定价和前置作业时间。因此，那些保持供应商多元化、投资于二级采购并实现关键能力内部化的公司，更有能力应对各种挑战。能够将临床疗效与可验证的工作流程改进以及清晰的经济效益相结合，从而引起医院管理者和综合医疗服务网络共鸣的机构，将日益获得竞争优势。

为加速推广应用、降低供应链风险并增强临床和商业性价值主张，可采取切实可行的策略性措施和营运措施。

产业领导者应采取一系列协调一致的策略行动，以解决产品设计、商业性准入和供应链韧性等问题。首先，应优先考虑模组化产品架构，以便进行增量升级并简化监理申报流程。其次，应投入资源，收集将设备性能与临床结果和营运指标连结起来的证据。现场试验、註册登记研究和手术全期工作流程研究将有助于医院和门诊中心更有力地论证采购理由。

第三，我们将考虑建立区域性製造地，以实现采购多元化并降低关税和物流风险。第四，我们将透过类比、导师製网路和数位化学习平台，加强外科医生培训，以提升临床医生的信心，并缩短新设备和新手术流程的推广应用週期。第五，我们将调整商业模式以适应终端用户需求，并透过为门诊中心提供捆绑式手术套件、为重症监护医院提供专业支持方案，使价值主张与买方奖励提案契合。

最后，要保持积极的监管沟通，并密切注意能量型和植入式组件相关标准的演变。儘早与监管和报销利益相关人员接洽，可以加快产品进入市场，同时确保临床数据收集能够支持长期监测和经济评估。这些措施共同构成了一个切实可行的蓝图，既兼顾了长期的临床和商业性差异化优势，也保证了短期营运的稳定性。

透过透明的混合方法研究框架获得可靠的见解，该框架整合了临床医生访谈、监管机构审查、供应链图谱和证据三角验证。

本研究采用混合方法，将质性研究与定量二手资料结合，以多角度分析设备性能、推广应用驱动因素和供应链脆弱性。主要资料来源包括对心臟外科医师、血管外科医师、采购负责人、临床营运负责人和生产主管的结构化访谈，并辅以手术室和设备训练模拟的观察资料。这些调查直接揭示了设备的易用性、部署挑战和临床医生的偏好。

二次研究包括对同行评审的临床文献、监管文件、专利概况和技术白皮书进行系统性回顾，以检验性能声明并追踪创新轨迹。供应链映射结合了海关数据、供应商名录和生产布局分析，以识别集中风险和潜在的近岸外包机会。透过对多个资料来源的研究结果进行交叉检验、对情境假设进行敏感性测试以及由临床和行业专家进行咨询审查，确保了调查方法和资料来源的严谨性。

本研究遵循伦理原则，所有专有资料均严格保密。此综合报告优先考虑可直接满足采购、研发和商业规划需求的实用讯息，确保检验均基于可观察的趋势和经实践验证的经验，而非依赖未经证实的说法。

将临床创新、营运韧性和商业策略连结起来的简明综合分析，有助于高阶主管对医疗器材专案做出自信的决策。

最后，心血管吻合器材领域正朝着兼顾临床疗效和操作效率的解决方案发展。材料和能量输送方面的创新，以及微创和机器人手术的普及，正在重新定义临床医生对器械的期望，同时也凸显了互通性和循证价值提案的重要性。供应链压力和不断变化的贸易政策进一步强调了灵活筹资策略和敏捷生产的重要性。

决策者若能将产品开发与明确的流程需求结合，投资于严谨的临床和经济证据，并采用稳健的生产和采购惯例，将更有利于实现永续的市场推广。同样，重视终端使用者培训、简化设备介面并采取有针对性的地域策略的机构，将能够加速在高潜力临床领域的推广应用。本文旨在为战术性选择和策略投资重点提供参考，从而推动改善患者预后并实现可持续的商业性绩效。

透过结合临床考量、供应链实际情况和竞争格局，该分析可以帮助高阶主管和临床领导者就投资方向、如何降低风险以及如何在不同的医疗保健环境中扩大创新规模做出深思熟虑、充满信心的决策。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合机器人辅助系统以提高冠状动脉吻合术的精确度
  • 开发生物可吸收连接器以减少血管吻合术中的长期异物反应
  • 使用无缝线磁压装置加速冠状动脉绕道手术（CABG）术后康復
  • 内视镜吻合工具的进步使得透过较小的切口进行微创旁路移植手术成为可能。
  • 3D列印患者特异性吻合导板的出现，有助于优化移植物对位并减少手术误差。
  • 整合感测器辅助吻合装置，用于即时监测移植血管通畅性和血流动力学
  • 医疗科技公司与人工智慧供应商合作开发用于预测吻合器性能和结果的预测分析技术
  • 监管核准和报销政策的改变促进了新型自动缝合器在心血管外科手术中的广泛应用。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 心血管吻合器材市场（依产品类型划分）

  • 夹子
    • 止血夹
      • 金属夹
      • 聚合物夹
    • 血管夹
  • 订书机
    • 圆形订书机
    • 直线型订书机
      • 未加固
      • 加强
  • 缝合器械
    • 自动缝合
      • 手持式缝合器械
      • 机器人缝合装置
    • 手工缝合

9. 心血管吻合装置市场（依机制划分）

  • 胶水
    • 纤维蛋白胶
    • 合成密封剂
  • 夹钳
  • 压缩
    • 吻合环
    • 扣上
      • 生物可吸收扣
      • 金属扣
  • 基于能源
    • 电暖型
    • 雷射
    • 超音波
  • 用订书钉装订

第十章 心血管吻合器械市场（依手术类型划分）

  • 冠状动脉绕道手术
    • 非泵送
    • 泵浦上
  • 週边血管
    • 颈动脉
    • 股腘动脉
    • 肾
  • 阀门维修

第十一章 心血管吻合器材市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

12. 心血管吻合器材市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 心血管吻合器材市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国心血管吻合器材市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Medtronic plc
    • Abbott Laboratories
    • TERUMO Corporation
    • Johnson & Johnson
    • WL Gore & Associates, Inc.
    • Baxter International Inc.
    • B. Braun Melsungen AG
    • Teleflex Incorporated
    • Getinge AB
    • CryoLife, Inc.
Product Code: MRR-8C74ADFBF9A7

The Cardiovascular Anastomosis Devices Market is projected to grow by USD 4.55 billion at a CAGR of 11.00% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.97 billion
Estimated Year [2025] USD 2.19 billion
Forecast Year [2032] USD 4.55 billion
CAGR (%) 11.00%

A clear and authoritative orientation to the current device ecosystem, clinical considerations, and operational priorities shaping cardiovascular anastomosis today

Cardiovascular anastomosis devices sit at the intersection of surgical technique, materials science, and systems-level healthcare delivery. This introduction frames the contemporary landscape of tools used to establish and secure vascular and cardiac connections during a wide range of procedures, highlighting the ways that device form factors, mechanism of action, and clinical workflows interact to influence outcomes. The discipline has advanced from manual suturing toward mechanized, energy-assisted, and hybrid solutions designed to standardize reproducibility, reduce operative time, and mitigate complications.

Across the portfolio of devices discussed here, clinicians and healthcare organizations increasingly evaluate performance not only by ease of use but by durability, hemostasis efficiency, and compatibility with minimally invasive and robotic approaches. The integration of new polymers, metals, and energy delivery systems has expanded options for surgeons while adding complexity to procurement, training, and regulatory pathways. As stakeholders adopt novel approaches, the balance between device efficacy, clinician ergonomics, and total procedure cost becomes central to commercial conversations.

This introduction sets expectations for the following sections: an analysis of the tectonic shifts reshaping practice, a scenario-based view of tariff impacts, segmentation-driven insights that clarify product and clinical niches, and regional and competitive intelligence designed to inform practical strategy. The aim is to equip decision-makers with clear thematic takeaways that support immediate tactical choices and mid-term strategic planning.

How minimally invasive trends, materials breakthroughs, device interoperability, and evolving procurement models are redefining surgical anastomosis practices

Several transformative shifts are reshaping how cardiovascular anastomosis devices are designed, adopted, and commercialized, with implications that extend across clinical, manufacturing, and reimbursement domains. First, the steady move toward minimally invasive and robotic-assisted surgery has increased demand for devices that provide consistent, reproducible anastomoses within constrained access corridors; this trend is accelerating iterative refinements in form factor, articulation, and integration with robotic platforms. As a result, product development now emphasizes modular interfaces and compatibility standards that allow quicker clinical adoption and lower training burden.

Second, materials innovation-ranging from polymer formulations for absorbable components to new alloys and coatings for hemostatic clips-has expanded device longevity and biocompatibility while enabling engineers to reduce profile footprint and improve deployment reliability. Concurrently, energy-based technologies such as electrothermal and ultrasonic modalities are being refined to deliver controlled tissue effects, reducing bleeding and shortening operative time when properly matched to the clinical indication.

Third, procurement dynamics are evolving as ambulatory surgery centers gain greater procedural volume and hospitals pursue value-based metrics; this has heightened focus on total procedural cost, inventory optimization, and interoperability with existing devices. Lastly, regulatory and clinical-evidence expectations are rising, driving firms to invest in robust comparative studies and real-world evidence generation that demonstrate not only safety and efficacy but also downstream economic and workflow benefits. Taken together, these forces are producing a market environment where technical differentiation, clinical validation, and distribution agility determine the leaders in device adoption.

A practical analysis of how evolving US tariff dynamics drive supply chain reengineering, pricing pressure, and opportunities for local manufacturing resilience

The imposition and escalation of tariffs originating from policy shifts in major markets can materially influence supply chain choices, sourcing strategies, and component economics for manufacturers and distributors of cardiovascular anastomosis devices. When import levies are introduced or increased, firms that rely on cross-border sourcing for precision metal components, advanced polymers, electronic control units, or robotic subsystems must reassess supplier relationships and inventory practices to maintain margin and availability.

In practical terms, tariffs often catalyze near-term cost passthrough to buyers or compression of supplier margins, creating pressure to redesign devices for fewer tariff-sensitive inputs or to qualify local manufacturers who can supply key subassemblies. Manufacturers may pursue regional production hubs or toll-manufacturing agreements to mitigate exposure to targeted levies. At the same time, elevated import costs can accelerate vertical integration for components with high tariff risk, prompting manufacturers to acquire or partner with specialized suppliers to secure continuity and reduce unit cost volatility.

Clinically, procurement teams and hospital systems respond to tariff-driven price changes by tightening evaluation criteria, increasing competitive bidding, and prioritizing multi-use or reusable solutions where appropriate. Reimbursement administrators and value committees may demand clearer evidence of cost-benefit under new input-cost realities. For innovation-driven companies, tariffs create both challenges and opportunities: while they can increase near-term commercial friction, they also incentivize product simplification, localization of sensitive supply chains, and the development of incremental improvements that reduce reliance on imported materials and finished goods. Thus, tariff scenarios should be integrated into strategic planning as an ongoing supply-chain and pricing risk that requires coordinated responses across procurement, regulatory affairs, and product development.

A multi-dimensional segmentation synthesis that aligns product type, mechanism, procedure, and end-user parameters to reveal precise clinical and commercial target zones

Understanding product and clinical niches requires a layered segmentation approach that clarifies where innovation and commercialization can most effectively be targeted. By product type, the device universe encompasses clips, staplers, and suture devices. Clips are used for rapid vessel control and are typified by hemostatic clips and ligating clips; hemostatic clips themselves are delivered in metal and polymer variants that trade off permanence and imaging compatibility. Staplers include circular and linear configurations, and within linear staplers manufacturers distinguish between non-reinforced and reinforced variants to address tissue thickness and leak resistance. Suture devices span automated suturing and manual suturing techniques, with the automated category further divided into handheld suturators and robotic suturators that target different levels of automation and procedural complexity.

By mechanism of action, devices are organized across adhesive solutions, clamping systems, compression mechanisms, energy-based modalities, and stapling. Adhesive technologies include biologic fibrin sealants and synthetic sealants, each offering distinct handling and hemostatic profiles. Compression strategies cover anastomotic rings and buckles, and buckles may be bioabsorbable or metal depending on the intended permanence. Energy-based devices deploy electrothermal, laser, or ultrasonic effects to seal tissue and control bleeding while minimizing collateral thermal injury.

By procedure type, device selection aligns with the clinical context: coronary bypass surgery-performed off-pump or on-pump-creates one set of anastomotic challenges, whereas peripheral vascular procedures such as carotid, femoropopliteal, and renal interventions demand devices optimized for vessel size, accessibility, and plaque burden. Valve repair procedures introduce additional anatomical and hemodynamic constraints that influence device selection and deployment technique. Finally, end-user segmentation highlights the delivery environment: ambulatory surgery centers, hospitals, and specialty clinics each impose distinct requirements in terms of device footprint, sterilization workflows, and staff training. Appreciating these interlocking segmentation layers enables firms to tailor product design, clinical evidence generation, and commercialization pathways to the realities of distinct clinical and operational settings.

How regional clinical priorities, regulatory environments, and supply chain footprints differentially influence device adoption across Americas, EMEA, and Asia-Pacific

Regional dynamics shape adoption pathways, regulatory hurdles, and supply-chain design in ways that affect strategy and execution. In the Americas, clinical emphasis on minimally invasive coronary and peripheral interventions intersects with a mature reimbursement infrastructure and sophisticated hospital purchasing processes. Providers in major markets prioritize devices that demonstrably reduce operating time, lower complication rates, and integrate with existing surgical platforms. Meanwhile, regional manufacturers and contract manufacturers play a significant role in providing localized supply and rapid replenishment, which benefits high-volume centers.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory alignment across countries and strong national procurement agencies can accelerate adoption when evidence is compelling, but fragmentation across markets requires tailored regulatory and reimbursement strategies. Several European markets have high expectations for real-world evidence and cost-effectiveness data, and procurement bodies often demand long-term safety information for devices intended to be permanent or semi-permanent.

Asia-Pacific is characterized by rapid growth in procedural volumes, expanding investment in hospital infrastructure, and a dual market structure that includes both high-end tertiary care centers and resource-constrained facilities. Local OEMs and regional supply chains are increasingly sophisticated, and multinational vendors often pursue partnerships or local production to meet regulatory and cost requirements. Across regions, companies that align product portfolios to local procedural patterns, regulatory timing, and purchasing models gain the clearest path to sustained adoption.

An incisive review of competitive positioning, partnership dynamics, supplier concentration, and the innovation pathways shaping device leadership

Competitive dynamics in cardiovascular anastomosis devices are shaped by a mix of incumbent medical-device firms, specialized mid-sized innovators, and a growing cohort of technology-focused startups. Established manufacturers leverage broad commercial channels, regulatory experience, and existing clinical relationships to scale distribution quickly, while smaller players advance disruptive features-such as advanced energy control algorithms, novel absorbable polymers, or compact robotic suturing modules-that attract early-adopter surgeons and strategic acquirers.

Partnerships and co-development agreements between device companies and robotic platform providers have intensified as both sides seek to ensure interoperability and bundled clinical value propositions. Cross-disciplinary collaboration between materials scientists, clinical researchers, and systems engineers has produced a pipeline of incremental innovations that improve handling, reduce device profile, and enhance hemostasis. At the same time, regulatory pathways emphasizing clinical evidence and post-market surveillance have raised the bar for new entrants, making clinical trial design, registry participation, and formal health-economics analysis essential components of go-to-market plans.

Supplier concentration for specialized components-precision stamping for metal clips, custom polymer extrusion, and microelectronics for energy delivery systems-creates strategic dependencies that influence pricing and lead times. Consequently, firms that maintain diversified supplier bases, invest in secondary sourcing, or internalize key capabilities are better positioned to manage disruption. Competitive advantage increasingly accrues to organizations that can pair clinical efficacy with demonstrable workflow improvements and clear economic narratives that resonate with hospital administrators and integrated delivery networks.

Practical strategic moves and operational measures to accelerate adoption, de-risk supply chains, and strengthen clinical and commercial value propositions

Industry leaders should adopt a coordinated set of strategic actions that address product design, commercial access, and supply-chain resilience. First, prioritize modular product architectures that enable incremental upgrades and simplified regulatory submissions; this reduces time-to-adoption and allows manufacturers to introduce targeted improvements without broad redesign. Second, invest in evidence generation that links device performance to clinical outcomes and operational metrics; pragmatic trials, registry participation, and perioperative workflow studies will strengthen purchasing cases in both hospitals and ambulatory centers.

Third, diversify sourcing and consider regional manufacturing footprints to mitigate tariff exposure and logistics risk; dual-sourcing agreements, qualified contract manufacturers in strategic geographies, and selective vertical integration for high-risk components will reduce vulnerability to trade disruptions. Fourth, enhance surgeon training pathways through simulation, proctoring networks, and digital learning platforms to accelerate clinician confidence and shorten the adoption curve for new devices or techniques. Fifth, tailor commercial models to end-user needs by offering bundled procedural kits for ambulatory centers and specialized support packages for high-acuity hospitals, thereby aligning value propositions with purchaser incentives.

Finally, maintain an active regulatory engagement plan and monitor evolving standards for energy-based and implantable components. Engaging early with regulators and reimbursement stakeholders can expedite market access while ensuring that clinical data collection supports long-term surveillance and economic assessment. Together, these actions form a pragmatic roadmap that balances near-term operational resilience with long-term clinical and commercial differentiation.

A transparent mixed-methods research framework integrating clinician interviews, regulatory review, supply-chain mapping, and evidence triangulation to ensure robust insights

The research applied a mixed-methods approach that triangulated primary qualitative engagement with quantitative secondary data to build a multi-perspective view of device performance, adoption drivers, and supply-chain vulnerabilities. Primary inputs included structured interviews with cardiac and vascular surgeons, procurement officers, clinical affairs leaders, and manufacturing executives, supplemented by observational inputs from procedure rooms and device training simulations. These engagements provided first-hand insights into device usability, deployment challenges, and clinician preferences.

Secondary research encompassed systematic reviews of peer-reviewed clinical literature, regulatory filings, patent landscapes, and technology white papers to validate performance claims and trace innovation trajectories. Supply-chain mapping combined customs data, supplier directories, and manufacturing footprint analysis to identify concentration risks and potential nearshoring opportunities. Methodological rigor was ensured through cross-validation of findings across multiple data sources, sensitivity testing of scenario assumptions, and advisory review by clinical and industry experts.

Ethical research practices were observed throughout, and proprietary data were handled under strict confidentiality protocols. The synthesis prioritized actionable intelligence that speaks directly to procurement, R&D, and commercial planning needs without relying on unverifiable claims, ensuring that recommendations are grounded in observable trends and corroborated practitioner experience.

A concise synthesis linking clinical innovation, operational resilience, and commercial strategy to inform confident executive decision-making in device programs

In closing, the cardiovascular anastomosis device landscape is transitioning toward solutions that harmonize clinical efficacy with operational efficiency. Innovations in materials and energy delivery, along with the spread of minimally invasive and robotic approaches, are redefining what clinicians expect from devices while amplifying the importance of interoperability and evidence-based value propositions. Supply-chain pressures and trade-policy shifts further underscore the need for flexible sourcing strategies and manufacturing agility.

Decision-makers who align product development with clear procedural needs, invest in rigorous clinical and economic evidence, and adopt resilient manufacturing and procurement practices will be best positioned to capture sustainable adoption. Equally, organizations that prioritize end-user training, simplified device interfaces, and targeted regional strategies can accelerate uptake in high-opportunity clinical segments. The synthesis presented here is intended to inform tactical choices and strategic investment priorities that drive both improved patient outcomes and durable commercial performance.

By bringing clinical insight, supply-chain realism, and competitive clarity together, this analysis supports executives and clinical leaders in making measured, high-confidence decisions about where to invest, how to mitigate risk, and how to scale innovations across diverse healthcare settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of robotic-assisted systems to enhance precision in coronary anastomosis procedures
  • 5.2. Development of bioabsorbable couplers for reducing long-term foreign body response in vessel anastomosis
  • 5.3. Adoption of sutureless magnetic compression devices to accelerate postoperative recovery in CABG surgeries
  • 5.4. Advancements in endoscopic anastomosis tools facilitating minimally invasive bypass graft procedures with smaller incisions
  • 5.5. Emergence of 3D-printed patient-specific anastomotic guides to optimize graft alignment and reduce surgical errors
  • 5.6. Integration of sensor-enabled anastomosis devices for real-time monitoring of graft patency and blood flow dynamics
  • 5.7. Collaborations between medtech firms and AI vendors to develop predictive analytics for anastomosis device performance and outcomes
  • 5.8. Regulatory approvals and reimbursement shifts driving uptake of novel automated stapling devices in cardiovascular surgery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiovascular Anastomosis Devices Market, by Product Type

  • 8.1. Clips
    • 8.1.1. Hemostatic Clips
      • 8.1.1.1. Metal Clips
      • 8.1.1.2. Polymer Clips
    • 8.1.2. Ligating Clips
  • 8.2. Staplers
    • 8.2.1. Circular Staplers
    • 8.2.2. Linear Staplers
      • 8.2.2.1. Non Reinforced
      • 8.2.2.2. Reinforced
  • 8.3. Suture Devices
    • 8.3.1. Automated Suturing
      • 8.3.1.1. Handheld Suturer
      • 8.3.1.2. Robotic Suturer
    • 8.3.2. Manual Suturing

9. Cardiovascular Anastomosis Devices Market, by Mechanism

  • 9.1. Adhesive
    • 9.1.1. Fibrin Sealants
    • 9.1.2. Synthetic Sealants
  • 9.2. Clamping
  • 9.3. Compression
    • 9.3.1. Anastomotic Rings
    • 9.3.2. Buckles
      • 9.3.2.1. Bioabsorbable Buckles
      • 9.3.2.2. Metal Buckles
  • 9.4. Energy Based
    • 9.4.1. Electrothermal
    • 9.4.2. Laser
    • 9.4.3. Ultrasonic
  • 9.5. Stapling

10. Cardiovascular Anastomosis Devices Market, by Procedure Type

  • 10.1. Coronary Bypass
    • 10.1.1. Off Pump
    • 10.1.2. On Pump
  • 10.2. Peripheral Vascular
    • 10.2.1. Carotid
    • 10.2.2. Femoropopliteal
    • 10.2.3. Renal
  • 10.3. Valve Repair

11. Cardiovascular Anastomosis Devices Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Cardiovascular Anastomosis Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cardiovascular Anastomosis Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cardiovascular Anastomosis Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Medtronic plc
    • 15.3.2. Abbott Laboratories
    • 15.3.3. TERUMO Corporation
    • 15.3.4. Johnson & Johnson
    • 15.3.5. W. L. Gore & Associates, Inc.
    • 15.3.6. Baxter International Inc.
    • 15.3.7. B. Braun Melsungen AG
    • 15.3.8. Teleflex Incorporated
    • 15.3.9. Getinge AB
    • 15.3.10. CryoLife, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. AMERIC